Kentucky Retirement Systems Has $5.96 Million Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Kentucky Retirement Systems decreased its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 1.4% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 34,385 shares of the company’s stock after selling 481 shares during the quarter. Kentucky Retirement Systems’ holdings in Zoetis were worth $5,961,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of ZTS. Webster Bank N. A. lifted its holdings in Zoetis by 89.1% in the 1st quarter. Webster Bank N. A. now owns 174 shares of the company’s stock worth $29,000 after purchasing an additional 82 shares during the last quarter. Neo Ivy Capital Management acquired a new stake in shares of Zoetis in the fourth quarter worth $40,000. LRI Investments LLC bought a new stake in shares of Zoetis during the 1st quarter worth $43,000. Ables Iannone Moore & Associates Inc. bought a new stake in shares of Zoetis during the 4th quarter worth $51,000. Finally, Hazlett Burt & Watson Inc. grew its stake in Zoetis by 60.7% in the 1st quarter. Hazlett Burt & Watson Inc. now owns 270 shares of the company’s stock valued at $46,000 after buying an additional 102 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Performance

NYSE:ZTS opened at $193.24 on Friday. The stock has a market capitalization of $88.17 billion, a P/E ratio of 37.23, a price-to-earnings-growth ratio of 2.98 and a beta of 0.88. The company has a current ratio of 3.45, a quick ratio of 2.09 and a debt-to-equity ratio of 1.32. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $201.92. The firm has a 50 day moving average of $184.42 and a 200-day moving average of $174.44.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Tuesday, August 6th. The company reported $1.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.49 by $0.07. The business had revenue of $2.36 billion during the quarter, compared to analysts’ expectations of $2.31 billion. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. During the same period in the previous year, the business posted $1.41 earnings per share. The firm’s revenue for the quarter was up 8.3% compared to the same quarter last year. As a group, sell-side analysts anticipate that Zoetis Inc. will post 5.84 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have weighed in on ZTS. Argus raised shares of Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. Stifel Nicolaus increased their target price on Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a research note on Wednesday. Piper Sandler lifted their price target on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 14th. Finally, BTIG Research increased their price objective on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research report on Monday, August 12th. Nine investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Zoetis presently has a consensus rating of “Buy” and a consensus price target of $220.38.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.